

U.S. Food and Drug Administration (FDA) Approved Remdesivir as the only Treatment for COVID-19

Cairo, October 25, 2020 – EVA Pharma announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Remdesivir for the treatment of COVID-19 patients requiring hospitalization.

Remdesivir had become now the first and only FDA-Approved treatment for COVID-19, as it was previously authorized by the FDA for emergency use to treat adult and pediatric hospitalized mild, moderate and severe COVID-19 patients. The drug is now widely available in many countries as it is manufactured by EVA Pharma, a licensed manufacturer for Remdesivir-EVA Pharma according to an agreement with Gilead Sciences Inc. The agreement provides EVA Pharma with Gilead's technology as well as manufacturing specifications and methods to accelerate the timeline of the production as soon as possible to export to 127 countries including Egypt.

As an antiviral drug, Remdesivir inhibit replication of SARS-CoV-2, the virus that causes COVID-19. The drug was investigated in three randomized control trials which showed clinically meaningful improvements with hospitalized COVID-19 patients as it shortened recovery time by five days.

Remdesivir has shown great results according to a clinical trial conducted by the U.S. National Institute of Allergy and Infectious Diseases investigating 1062 hospitalized COVID-19 patients. The study showed the median time to recovery was 10 days for the Remdesivir group compared to 15 days for the placebo group. Other trials have revealed a reduced “mortality rate” when patients are treated with Remdesivir.

“The results of remdesivir use in Egypt match the global results” said Dr. Hossam Hosny, head of the Anti-Coronavirus Scientific Committee at the Ministry of Health and Population, as he anticipated the expand in remdesivir use last September in a scientific conference attended by Minister of Health Dr. Hala Zayed, and presidential advisor for health affairs, Dr. Mohamed Awad Tag El-Den.

About EVA Pharma:

EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo, Egypt while operating in more than 40 countries and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 42 countries throughout the region. With a 3,000-strong team of some of the region's most competent pharmaceutical professionals, EVA Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards.